Arvee Laboratories (India) Limited
: ARVEE · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Arvee Laboratories (India) Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Arvee Laboratories (India) Ltd is a specialty chemicals manufacturer established in 2012. The company focuses on the production of polymer modifiers, contrast media intermediates, and various drug intermediates.
Business Model
The company generates revenue through the manufacturing and sale of specialized chemical compounds used in polymer science, diagnostic imaging, and pharmaceutical synthesis.
Growth Outlook
Growth is primarily driven by the increasing demand for high-purity chemical intermediates in the pharmaceutical and polymer industries.
Key Risks
- Regulatory Compliance. The chemical manufacturing sector is subject to stringent environmental and safety regulations that may impact operational costs.
- Raw Material Price Volatility. Fluctuations in the prices of petrochemical feedstocks can significantly affect profit margins.
- Market Competition. The company faces intense competition from both domestic and international players in the specialty chemicals space.
- Dependency on Pharmaceutical Sector. A significant portion of the product portfolio is linked to drug intermediates, making the company sensitive to trends in the global pharmaceutical industry.
Start your research today
Unlock AI insights, financials, peers and live data on Arvee Laboratories (India) Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹32 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
EPS
₹2.29
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.8%
TTM · standalone
P/E
69.0x
Q4 FY26 · standalone
EV/EBITDA
42.3x
Q4 FY26 · standalone
EBITDA MARGIN
12.2%
TTM · standalone
NET PROFIT MARGIN
4.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Arvee Laboratories (India) LimitedARVEE | ₹186 Cr | 73.80 | 48.55 | -18.1% | 12.2% | 7.9% | 7.8% | +5.1% |
Kronox Lab Sciences LimitedKRONOX | ₹666 Cr | 23.05 | 16.30 | 6.1% | 38.7% | 27.7% | 35.9% | +11.2% |
Black Rose IndusBLACKROSE | ₹584 Cr | 26.01 | 16.40 | — | 11.0% | 13.9% | 18.9% | +19.1% |
Vipul OrganicsVIPULORG | ₹506 Cr | 63.11 | 30.62 | 7.7% | 10.4% | 8.9% | 13.4% | +29.6% |
Plastiblends India LimitedPLASTIBLEN | ₹493 Cr | 11.54 | 6.83 | 5.5% | 9.2% | 9.7% | 12.8% | +0.5% |
Aarti SurfactantAARTISURF | ₹458 Cr | 24.91 | 9.80 | 25.2% | 6.1% | 7.7% | 12.4% | +19.0% |
As of Q4 FY26
Financials
Arvee Laboratories (India) Limited
: ARVEE · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Arvee Laboratories (India) Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Arvee Laboratories (India) Ltd is a specialty chemicals manufacturer established in 2012. The company focuses on the production of polymer modifiers, contrast media intermediates, and various drug intermediates.
Business Model
The company generates revenue through the manufacturing and sale of specialized chemical compounds used in polymer science, diagnostic imaging, and pharmaceutical synthesis.
Growth Outlook
Growth is primarily driven by the increasing demand for high-purity chemical intermediates in the pharmaceutical and polymer industries.
Key Risks
- Regulatory Compliance. The chemical manufacturing sector is subject to stringent environmental and safety regulations that may impact operational costs.
- Raw Material Price Volatility. Fluctuations in the prices of petrochemical feedstocks can significantly affect profit margins.
- Market Competition. The company faces intense competition from both domestic and international players in the specialty chemicals space.
- Dependency on Pharmaceutical Sector. A significant portion of the product portfolio is linked to drug intermediates, making the company sensitive to trends in the global pharmaceutical industry.
Start your research today
Unlock AI insights, financials, peers and live data on Arvee Laboratories (India) Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹32 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
EPS
₹2.29
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.8%
TTM · standalone
P/E
69.0x
Q4 FY26 · standalone
EV/EBITDA
42.3x
Q4 FY26 · standalone
EBITDA MARGIN
12.2%
TTM · standalone
NET PROFIT MARGIN
4.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Specialty Chemicals
As of Q4 FY26